BIOMIND LABS INC BMND

BMNDNEO
BMND
BIOMIND LABS INCNEO
 
No trades
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Finance
Industry: Investment Banks/Brokers
Biomind Labs, Inc. is a biotech research and development company focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND02 ? N, N-dimethytryptamine that is in Phase II clinical trials for use in the treatment of depression; and BMND01 ? Ayahuasca, a product candidate in pre-clinical trials for use in the treatment of smoking addiction. Its product candidates in evaluation stage include BMND03 ? Psilocybin for treating chronic pain; BMND04 ? Mescaline for treating eating disorders and neurodegenerative diseases; and BMND05 ? 5-MeO-DMT, an anti-inflammatory product. The company was founded in 2021 and is headquartered in Toronto, Canada.